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Background
Molecular Breast Imaging (MBI) is increasingly being used as an 
adjunct imaging modality in the detection of breast cancer. 1 A 
meta-analysis in 2013 from 8 studies, including 2183 lesions, 
showed that the sensitivity and specificity of MBI were 95% and 
80%, respectively. 2 Patients received an intravenous injection of 
Tc-99m-sestamibi, and a gamma camera was used to obtain 
Craniocaudal (CC) and mediolateral oblique (MLO) projections.
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Figure 1A – 80-year-old woman with a mass lesion on homogeneous BPU, 
diagnosed as ductal carcinoma in situ in the right breast.
Figure 1B – 53-year-old woman with a mass lesion on heterogeneous BPU, 
diagnosed as invasive ductal carcinoma on the right breast.
Figure 1C – 68-year-old woman with a non-mass lesion on homogeneous 
BPU, diagnosed with invasive ductal carcinoma with a component of 
ductal carcinoma in situ on the left breast.
Figure 1D – 48-year-old woman with a non-mass lesion on heterogeneous 
BPU, diagnosed as invasive ductal carcinoma with a component of ductal 
carcinoma in situ on the right breast.
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A retrospective review was performed on 193 suspicious 
findings from 153 women (31-81 years) with positive MBI 
examinations. We assessed associations between: 
(i) Lesion pattern (mass vs. non-mass) and positive predictive 
value (PPV)
(ii) Lesion pattern and suspected likelihood of cancer (low vs. 
moderate vs. high)
(iii) Background parenchymal uptake (BPU) (homogeneous vs. 
heterogeneous) and PPV
(iv) Breast density (dense vs. non-dense) and PPV
(v) BPU and density
Methods
Results
110/153 patients were diagnosed with malignant or high-risk 
pathology (PPV1 = 71.9%), and 130/193 biopsies resulted in 
malignant or high-risk lesions (PPV3 = 67.4%). 
(i) Biopsies of mass vs. non-mass findings had comparable PPV3
(71.7% vs. 61.3%; P = 0.0717). 
(ii) Mass findings were correlated with higher suspicion for 
cancer than non-mass findings (P < 0.001). 
(iii) There was no significant difference in PPV3 between 
biopsies from homo vs. hetero BPU (72.5% vs. 60.7%; P = 
0.103). No association was found between BPU and the 
diagnosis of cancer or high-risk pathology (P = 0.513). 
(iv) Biopsies from non-dense breasts had higher PPV3 than from 
dense breasts (85.4% vs 60.6%; P = 0.0025); patients with 
non-dense breasts were more likely to yield cancer or high-
risk pathology (PPV1 = 87.8% vs. 66.0%; P = 0.00844). 
(v) Dense breasts had greater association with heterogeneous 
BPU (P = 0.0844) than non-dense breasts.
Table 1 - Pathology of Malignant and High-risk Lesions Detected 
Using MBI
Conclusion
Understanding PPV of MBI in correlation to the character of 
lesions, BPU, and breast density provides a useful 
framework for interpretation and risk-stratification. Our 
study demonstrated that variability in mass or non-mass 
character of positive MBI findings may affect clinical 
suspicion but was not a useful determinant for probability of 
malignancy. Additionally, homogeneous vs. heterogeneous 
BPU did not significantly affect predictability of positive MBI 
images. Lastly, dense breasts yielded more false positives, 
likely due to the association with heterogeneous BPU. 
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Malignant Types # of Lesions # of Mass # of Non-Mass
Ductal carcinoma in situ 35 18 17
Invasive ductal carcinoma 24 21 3
Invasive ductal carcinoma with a 
component of ductal carcinoma in situ
44 31 13
Invasive lobular carcinoma 8          4 4
Total 111 74 37
High-risk Types # of Lesions # of Mass # of Non-Mass
Atypical ductal hyperplasia 6 4 2
Atypical lobular hyperplasia 5 3 2
Lobular carcinoma in situ 3 0 3
Papillomatosis 3 0 3
Radial Scar 2 0 2
Total 19 7 12
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